About Transition Bio
Transition Bio is a private company based in Cambridge, Massachusetts, incorporated in 2020 in Delaware. It has reported $58,351,426 raised in three offerings on Form D since April 2022.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 11, 2024 | Oct 25, 2024 | $13,265,426of $21.2M target | 8 | $1.6M | EquityRule 506(b) | Form D ↗ |
| Dec 22, 2023 | Jan 10, 2024 | $6,000,000of $15.0M target | 5 | $1.2M | Debt, OptionsRule 506(b) | Form D ↗ |
| Mar 24, 2022 | Apr 8, 2022amended Mar 7, 2023 | $39,086,000of $50.0M target | 22 | $1.7M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, three offerings | $58,351,426 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Transition Bio's Form D filed Oct 25, 2024.
TK
Tuomas Knowles
Director
KY
Kathy Yi
Director
RW
Robert Weeks
Director
GM
George Martin
Executive officer and director
AS
Al Sandrock
Director
ST
Stephanie Torruella
Secretary
SC
Samuel Cohen
Director
PM
Preet Makkar
Executive officer
PM
Paxton Major
Director
Earlier filings also listed Connor McDermott (director, last listed Jan 2024), Martin Kulander (executive officer, last listed Mar 2023) and Gregory Miller (chief executive officer and director, last listed Mar 2023).